SGMOQ
SGMOQ clinical trials: SANGAMO THERAPEUTICS, INC
Every trial on ClinicalTrials.gov where SANGAMO THERAPEUTICS, INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 30
- Trials linked
- 28
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
SGMOQ on the catalyst calendar · SGMOQ registry changes
- Primary completion Jul 2027Sponsor estimatePhase 1/Phase 2NCT06980948Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)Sangamo Therapeutics · Chronic Neuropathic PainSuspendedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2025ActualPhase 1/Phase 2NCT04046224Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)Sangamo Therapeutics · Fabry DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimateNo phase registeredNCT05039866Long-Term Follow-up of Subjects Who Were Treated With ST-920Sangamo Therapeutics · Fabry DiseaseActive, not recruitingSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2026ActualNo phase registeredNCT04628871Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXSangamo Therapeutics · Hemophilia BTerminatedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 11, 2024ActualPhase 1/Phase 2NCT04817774Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant RecipientsSangamo Therapeutics · Kidney Transplant RejectionCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 11, 2039Sponsor estimateNo phase registeredNCT05987527Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Sangamo Therapeutics · Kidney Transplant RejectionActive, not recruitingSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 14, 2038Sponsor estimateNo phase registeredNCT05145062Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.Sangamo Therapeutics · Blood and Lymphatic DiseasesActive, not recruitingSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2025ActualPhase 1/Phase 2NCT03653247A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients...Sangamo Therapeutics · Sickle Cell DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 19, 2021ActualPhase 1NCT02695160Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia BSangamo Therapeutics · Hemophilia BTerminatedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 17, 2023ActualNo phase registeredNCT04201782Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-TSangamo Therapeutics · HIV-1-infectionTerminatedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2022ActualPhase 1/Phase 2NCT03432364A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)Sangamo Therapeutics · Transfusion Dependent Beta-thalassemiaCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 3, 2021ActualPhase 1/Phase 2NCT02702115Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS ISangamo Therapeutics · MPS ITerminatedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2008ActualPhase 2NCT00400634Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's DiseaseSangamo Therapeutics · Idiopathic Parkinson's DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2007ActualPhase 1NCT00252850Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's DiseaseSangamo Therapeutics · Parkinson's DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2010ActualPhase 1NCT00087789CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseSangamo Therapeutics · Alzheimer's DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2021ActualPhase 1/Phase 2NCT03041324Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS IISangamo Therapeutics · Mucopolysaccharidosis IITerminatedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2015ActualPhase 2NCT01079325Clinical Trial of SB-509 in Subjects With Diabetic NeuropathySangamo Therapeutics · Diabetes Mellitus, Type 1CompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2017ActualPhase 1/Phase 2NCT01543152Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-TSangamo Therapeutics · HIVCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2018ActualPhase 1/Phase 2NCT02225665Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAARTSangamo Therapeutics · Human Immunodeficiency Virus (HIV)CompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 13, 2015ActualPhase 2NCT00876863Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseSangamo Therapeutics · Alzheimer's DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 9, 2014ActualPhase 1/Phase 2NCT00985517Safety and Efficacy of CERE-120 in Subjects With Parkinson's DiseaseSangamo Therapeutics · Idiopathic Parkinson's DiseaseCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1/Phase 2NCT01252641Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected SubjectsSangamo Therapeutics · HIVCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualPhase 1NCT01044654Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected PatientsSangamo Therapeutics · HIV InfectionCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2010ActualPhase 2NCT00748501Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)Sangamo Therapeutics · Amyotrophic Lateral SclerosisCompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2009ActualPhase 2NCT00665145Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509Sangamo Therapeutics · Diabetes Mellitus, Type 1CompletedSGMOQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 5 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner